206 related articles for article (PubMed ID: 33428936)
1. Proteomic identification and validation of novel interactions of the putative tumor suppressor PRELP with membrane proteins including IGFI-R and p75NTR.
Kosuge H; Nakakido M; Nagatoishi S; Fukuda T; Bando Y; Ohnuma SI; Tsumoto K
J Biol Chem; 2021; 296():100278. PubMed ID: 33428936
[TBL] [Abstract][Full Text] [Related]
2. Small leucine rich repeat proteoglycans (SLRPs) in the human sclera: identification of abundant levels of PRELP.
Johnson JM; Young TL; Rada JA
Mol Vis; 2006 Sep; 12():1057-66. PubMed ID: 17093390
[TBL] [Abstract][Full Text] [Related]
3. A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells.
Mikaelsson E; Österborg A; Jeddi-Tehrani M; Kokhaei P; Ostadkarampour M; Hadavi R; Gholamin M; Akhondi M; Shokri F; Rabbani H; Mellstedt H
PLoS One; 2013; 8(6):e67601. PubMed ID: 23826326
[TBL] [Abstract][Full Text] [Related]
4. The leucine-rich repeat protein PRELP binds fibroblast cell-surface proteoglycans and enhances focal adhesion formation.
Bengtsson E; Lindblom K; Tillgren V; Aspberg A
Biochem J; 2016 May; 473(9):1153-64. PubMed ID: 26920026
[TBL] [Abstract][Full Text] [Related]
5. The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor.
Bengtsson E; Mörgelin M; Sasaki T; Timpl R; Heinegård D; Aspberg A
J Biol Chem; 2002 Apr; 277(17):15061-8. PubMed ID: 11847210
[TBL] [Abstract][Full Text] [Related]
6. Proline/arginine-rich end leucine-rich repeat protein converts stem cells to ligament tissue and Zn(II) influences its nuclear expression.
Tsuru M; Soejima T; Shiba N; Kimura K; Sato K; Toyama Y; Nagata K
Stem Cells Dev; 2013 Jul; 22(14):2057-70. PubMed ID: 23442027
[TBL] [Abstract][Full Text] [Related]
7. Repression of the PRELP gene is relieved by histone deacetylase inhibitors through acetylation of histone H2B lysine 5 in bladder cancer.
Shozu K; Kaneko S; Shinkai N; Dozen A; Kosuge H; Nakakido M; Machino H; Takasawa K; Asada K; Komatsu M; Tsumoto K; Ohnuma SI; Hamamoto R
Clin Epigenetics; 2022 Nov; 14(1):147. PubMed ID: 36371227
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the human proline/arginine-rich end leucine-rich repeat protein (PRELP) gene promoter and identification of a repressor element.
Grover J; Roughley PJ
Biochem J; 1998 Nov; 336 ( Pt 1)(Pt 1):77-82. PubMed ID: 9806887
[TBL] [Abstract][Full Text] [Related]
9. The amino-terminal part of PRELP binds to heparin and heparan sulfate.
Bengtsson E; Aspberg A; Heinegard D; Sommarin Y; Spillmann D
J Biol Chem; 2000 Dec; 275(52):40695-702. PubMed ID: 11007795
[TBL] [Abstract][Full Text] [Related]
10. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
[TBL] [Abstract][Full Text] [Related]
11. PRELP, collagen, and a theory of Hutchinson-Gilford progeria.
Lewis M
Ageing Res Rev; 2003 Jan; 2(1):95-105. PubMed ID: 12437997
[TBL] [Abstract][Full Text] [Related]
12. Small Leucine-Rich Proteoglycans (SLRPs) in the Retina.
Low SWY; Connor TB; Kassem IS; Costakos DM; Chaurasia SS
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298915
[TBL] [Abstract][Full Text] [Related]
13. PRELP Enhances Host Innate Immunity against the Respiratory Tract Pathogen
Liu G; Ermert D; Johansson ME; Singh B; Su YC; Paulsson M; Riesbeck K; Blom AM
J Immunol; 2017 Mar; 198(6):2330-2340. PubMed ID: 28148731
[TBL] [Abstract][Full Text] [Related]
14. Characterization and expression of murine PRELP.
Grover J; Roughley PJ
Matrix Biol; 2001 Dec; 20(8):555-64. PubMed ID: 11731272
[TBL] [Abstract][Full Text] [Related]
15. PRELP (proline/arginine-rich end leucine-rich repeat protein) promotes osteoblastic differentiation of preosteoblastic MC3T3-E1 cells by regulating the β-catenin pathway.
Li H; Cui Y; Luan J; Zhang X; Li C; Zhou X; Shi L; Wang H; Han J
Biochem Biophys Res Commun; 2016 Feb; 470(3):558-562. PubMed ID: 26809092
[TBL] [Abstract][Full Text] [Related]
16. Expression of small leucine-rich proteoglycans in rat anterior pituitary gland.
Horiguchi K; Syaidah R; Fujiwara K; Tsukada T; Ramadhani D; Jindatip D; Kikuchi M; Yashiro T
Cell Tissue Res; 2013 Jan; 351(1):207-12. PubMed ID: 23100035
[TBL] [Abstract][Full Text] [Related]
17. AAV-mediated expression of human PRELP inhibits complement activation, choroidal neovascularization and deposition of membrane attack complex in mice.
Birke MT; Lipo E; Adhi M; Birke K; Kumar-Singh R
Gene Ther; 2014 May; 21(5):507-13. PubMed ID: 24670995
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis.
Chacón-Solano E; León C; Carretero M; García M; Sánchez-Domínguez R; Quero F; Méndez-Jiménez E; Bonafont J; Ruiz-Mezcua B; Escámez MJ; Larcher F; Del Río M
Matrix Biol; 2022 Aug; 111():189-206. PubMed ID: 35779740
[TBL] [Abstract][Full Text] [Related]
19. PRELP protein inhibits the formation of the complement membrane attack complex.
Happonen KE; Fürst CM; Saxne T; Heinegård D; Blom AM
J Biol Chem; 2012 Mar; 287(11):8092-100. PubMed ID: 22267731
[TBL] [Abstract][Full Text] [Related]
20. Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma.
Schäfer H; Subbarayan K; Massa C; Vaxevanis C; Mueller A; Seliger B
J Transl Med; 2023 Sep; 21(1):643. PubMed ID: 37730606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
